BioMarin Pharmaceutical Inc. announced today that the USPTO has issued patents covering stable tablet formulation and the approved once daily dosing regimen for Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria (PKU).
The details can be read here.
No comments:
Post a Comment